Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study
Frontiers in Immunology · 06.11.2025 · 16
DOI: 10.3389/fimmu.2025.1685233 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers in Immunology, online erschienen am 06.11.2025. Verfasst von Ye Hong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Fc. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Target-specific immunotherapies have been shown to effectively treat myasthenia gravis (MG) with less side effects. One such immunotherapy is efgartigimod, a neonatal Fc receptor antagonist, promotes degradation of pathogenic IgG antibodies. However, data specifically focusing on elderly, especially for those over 80 years, remain limited.
Methods
This study included generalized MG patients over 80 years old from four neuromuscular centers who were treated with efgartigimod. Data regarding MG history, treatment regimens, and scores from the MG-ADL, QMG, and MGC scales, as well as adverse events, were prospectively recorded.
Results
Twelve patients with mean age of 82.9 ± 2.5 years were included. Anti-AChR antibodies were positive in 11 patients and anti-MuSK antibodies were detected in 1 patient. All patients received at least one cycle of efgartigimod treatment, for the following indications: myasthenia gravis acute exacerbation (MGAE, n=8), mild/moderate disease (n=3), and myasthenic crisis (MC, n=1). At week 4 (1week after the final infusion), the study showed significant reductions in all efficacy measurements: MG-ADL scores decreased by 52.2% ± 30.8% (from 10.9 ± 2.7 to 3.6 ± 2.1), QMG scores by 36.6% ± 28.4% (from 18.2 ± 7.0 to 11.7 ± 8.3), MGC scores by 48.2% ± 33.4% (from 17.8 ± 7.5 to 9.0 ± 8.6). The greatest improvement was observed in the MGAE subgroup, with reductions of 69.8% ± 16.9% in MG-ADL, 51.8% ± 20.6% in QMG, 66.5% ± 20.2% in MGC. Clinically meaningful improvement (CMI) was rapidly achieved by 91.7% (11/12) of patients at 1.3 ± 0.5 weeks, with 8.3% (1/12) reaching minimal symptom expression (MSE) by week 4. However, two patients in the mild/moderate group failed to sustain CMI through week 4, resulting in nine responders overall (8 MGAE, 1mild/moderate). These responders maintained symptom control throughout the 24-week follow-up with subsequent therapies. Treatment-related adverse events were mild: two patients experienced transient minor headache and one patient had mild upper respiratory tract infection.
Conclusions
This multicenter study demonstrated that efgartigimod was efficacious and safe in the elderly MG over 80 years of age. Elderly patients with MGAE presented to benefit the most from efgartigimod treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Neurology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
- Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zitieren
APA
Hong, Y., Yuan, C. W., Lu, J., Kong, P. P., Huang, S. Q., Yang, R. Y., Yuan, Z. H., Zhao, H. D., Jiang, T., Chen, J., & Shi, J. Q. (2025). Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1685233
Vancouver
Hong Y, Yuan CW, Lu J, Kong PP, Huang SQ, Yang RY, et al. Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1685233
BibTeX
@article{Hong2025,
author = {Hong, Ye and Yuan, Chang-Wen and Lu, Jie and Kong, Ping-Ping and Huang, Shi-Qi and Yang, Rui-Yuan and Yuan, Zhen-Hua and Zhao, Hong-Dong and Jiang, Teng and Chen, Jing and Shi, Jian-Quan},
title = {Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1685233}
}
EUVIMED